# Imiquimod Cream Market

> Imiquimod cream: USD 122.7 million in 2025, growing 1.68% a year as ageing skin lifts AK and basal cell carcinoma courses despite generic price erosion.

Publisher: Douglas Insights  
Author: Douglas Insights Research Desk  
Report code: DI-HC-10465  
Published: 2026-10-04  
Last updated: 2026-10-04  
Next review: Apr 2027  
Page: https://www.douglasinsights.com/imiquimod-cream-market/

## Key figures

| Measure | Value | How it is built |
| --- | --- | --- |
| Market size · 2025 | $122.7 Mn | 4.32 million packs x USD 28.40 per pack = USD 122.7 million |
| Forecast · 2035 | $144.9 Mn | USD 144.9 million in the base case |
| Revenue CAGR · 2026-2035 | 1.68% | Multiplicative pack and price legs |
| Volume · 2035 | 5.58 million packs | 4.32 million packs growing 2.6% a year |
| Leading segment | Actinic keratosis | 51.8% share, USD 63.6 million in 2025 |
| Fastest segment | Superficial basal cell carcinoma | 2.96% a year to USD 27.1 million |
| Fastest region | Asia Pacific | 2.79% a year to USD 42.3 million |
| Market leader | Viatris | About 15.8% of value by Douglas Insights estimate |
| Event | Zyclara 3.75% shortage in Canada | 5 November 2024 to 5 August 2025, Drug Shortages Canada |

## Key takeaways

- Imiquimod cream earns USD 122.7 million in 2025 and USD 144.9 million in 2035, a 1.68% revenue CAGR from 2.6% pack growth and minus 0.9% price.
- Actinic keratosis holds 51.8% of value, while superficial basal cell carcinoma grows fastest at 2.96% a year.
- Europe leads with 44.5% of value, and Asia Pacific grows fastest at 2.79% a year.
- Medicare paid 25.9% less per generic imiquimod claim in 2024 than in 2023 while claims rose 14.5%.
- Zyclara 3.75% was short in Canada for 273 days, from 5 November 2024 to 5 August 2025.

A single-use sachet of 5% imiquimod cream holds 250 mg of cream carrying 12.5 mg of imiquimod, in a base of isostearic acid, cetyl and stearyl alcohols and white soft paraffin, according to the [Aldara summary of product characteristics](https://www.medicines.org.uk/emc/product/823/smpc). The Imiquimod Cream Market covers prescription imiquimod creams at 5%, 3.75% and 2.5% strength, sold in sachets and metered pumps for actinic keratosis (AK), superficial basal cell carcinoma (sBCC) and external genital and perianal warts. On Douglas Insights estimates, 4.32 million dispensed packs at a realised USD 28.40 each make USD 122.7 million in 2025; revenue then compounds at 1.68% a year over 2026-2035 to USD 144.9 million in 2035. Supply is thin at the brand end: the Canadian [drug shortage database](https://healthproductshortages.ca/shortage/237210) logged a Zyclara 3.75% shortage starting 5 November 2024, blamed on a production delay, with supply restored and the shortage record completed on 5 August 2025. Readers tracking topical generics can browse our [pharmaceuticals coverage](https://www.douglasinsights.com/industry/healthcare/pharmaceuticals/), and every number here is built under the [Douglas Insights research methodology](https://www.douglasinsights.com/research-methodology/).

## Why are actinic keratosis caseloads in older skin lifting imiquimod cream demand?

Imiquimod cream packs grow 2.6% a year to 2035, and older, sun-damaged skin is the main engine. Rising AK and sBCC caseloads supply 1.2 points of that growth. Asia Pacific generic access adds 0.8 points, and payer step therapy toward the 5% sachet adds 0.6 points.

Actinic keratosis is common in the age band that dominates dermatology lists. NHS Scotland's [primary care AK pathway](https://www.rightdecisions.scot.nhs.uk/shared-content/cfsd/dermatology/actinic-keratosis/) cites UK studies in which 19-24% of people over 60 had at least one AK, and it lists imiquimod 5% three times weekly for 4 weeks among the first-line field creams. Every year that cohort grows, more courses of 12 sachets are written, and the label allows a second course after a 4-week break. Douglas Insights puts this ageing effect at 1.2 points of the 2.6% volume leg, the largest single contribution, because AK is also 51.8% of imiquimod cream value.

Basal cell carcinoma adds a second, heavier course. The 5% label for sBCC is five applications a week for 6 weeks, or 30 sachets, two and a half times an AK course. In US Medicare Part D, generic imiquimod claims rose from 186,313 in 2023 to 213,392 in 2024, a 14.5% jump in one year, according to the [CMS Part D spending by drug file](https://catalog.data.gov/dataset/medicare-part-d-spending-by-drug). Douglas Insights reads part of that rise as older patients choosing topical field treatment over a surgical visit, though the CMS file does not give a reason, and the sBCC indication is the fastest-growing line in our model at 2.96% a year.

Asia Pacific supplies the second driver. Japan has a locally marketed 5% imiquimod cream, and Douglas Insights expects lower-priced generic sachets to reach more dermatology clinics in markets where branded cream was costly. We put the Asia Pacific contribution at 0.8 points of volume growth, and the region compounds at 2.79% a year, faster than any other.

Payer rules supply the third. Mass General Brigham Health Plan, a Massachusetts commercial insurer, covers imiquimod 5% cream without prior authorisation but requires a failed 5% trial before paying for 3.75% cream or pumps. Rules of that kind keep the cheap sachet as the default first script and add volume at the low end, because a USD 14.64 carton clears utilisation review without paperwork. Douglas Insights models this routing effect at 0.6 points, which closes the 2.6% volume leg: 1.2 plus 0.8 plus 0.6.

## What limits imiquimod cream as genital wart caseloads and brand sales shrink?

Imiquimod cream loses 1.1 points of pack growth to two volume brakes and 0.9% a year of price to a third. Douglas Insights nets 0.6 points off for falling genital wart caseloads and 0.5 points for competing AK field therapies, while generic sachet erosion drags realised price.

Genital warts are the restraint on the oldest indication. Human papillomavirus (HPV) vaccination cohorts are now in the age band that once filled sexual health clinics, so the external genital and perianal warts segment grows only 0.43% a year in our model, from USD 38.9 million to USD 40.6 million. That line removes 0.6 points from what volume growth would otherwise be.

Competing field creams are the second restraint. The same [NHS Scotland pathway](https://www.rightdecisions.scot.nhs.uk/shared-content/cfsd/dermatology/actinic-keratosis/) lists fluorouracil 5% twice daily for 3 to 4 weeks, diclofenac gel for 60 to 90 days, tirbanibulin once daily for 5 days and photodynamic therapy (PDT) by referral alongside imiquimod. A 5-day tirbanibulin course competes directly with a 4-week imiquimod course on convenience. Douglas Insights calculates 0.5 points of imiquimod cream volume lost to this switching.

Price erosion is the third and largest. Medicare Part D spending on generic imiquimod fell 15.2% between 2023 and 2024, from USD 8.60 million to USD 7.30 million, even as claims rose, per the [CMS file](https://catalog.data.gov/dataset/medicare-part-d-spending-by-drug). Spend per claim dropped from USD 46.18 to USD 34.20, a 25.9% fall. We build that into a price leg of minus 0.9% a year, after a small uplift from the 3.75% mix.

## Which indication makes the money for imiquimod cream, actinic keratosis or basal cell carcinoma?

Actinic keratosis makes the money, with 51.8% of imiquimod cream value, or USD 63.6 million in 2025. Genital warts follow at USD 38.9 million and sBCC at USD 20.2 million. AK leads because its courses repeat across a large, ageing patient base.

| Indication segment | Share 2025 | Value 2025 | CAGR 2026-2035 | Value 2035 |
| --- | --- | --- | --- | --- |
| Actinic keratosis | 51.8% | USD 63.6 million | 2.07% | USD 78.0 million |
| External genital and perianal warts | 31.7% | USD 38.9 million | 0.43% | USD 40.6 million |
| Superficial basal cell carcinoma | 16.5% | USD 20.2 million | 2.96% | USD 27.1 million |

Actinic keratosis holds 51.8%, worth USD 63.6 million, because one patient can need a second 4-week imiquimod course after a 4-week break, and because a 3.75% two-week cycle regimen also targets this indication. The segment grows 2.07% a year to USD 78.0 million in 2035.

External genital and perianal warts hold 31.7%, or USD 38.9 million. Courses run three times a week for up to 16 weeks, so each patient can use up to 48 sachets, which keeps value high even as new cases thin out.

Superficial basal cell carcinoma holds 16.5%, worth USD 20.2 million, and is the fastest-growing segment at 2.96% a year. A 6-week course of 30 sachets is an alternative to a surgical visit for suitable low-risk lesions, and Douglas Insights expects more older patients to take that option. The segment reaches USD 27.1 million by 2035.

By strength, 5% sachets carry most imiquimod packs, while 3.75% pumps and sachets carry a value premium and 2.5% cream is a minor line. By channel, retail pharmacy dispenses most packs, with hospital pharmacy and online pharmacy taking the remainder.

## Where are imiquimod sachets dispensed most, and which region gains fastest?

Europe is the largest region for imiquimod cream, at USD 54.6 million or 44.5% of 2025 value. Branded Aldara sachets still sell at tariff prices there. Asia Pacific is the fastest-growing region, at 2.79% a year, as generic sachets widen access through 2035.

Europe holds USD 54.6 million in 2025 and grows 1.21% a year to USD 61.6 million. The UK Drug Tariff lists a 12-sachet box of imiquimod 5% at GBP 48.60, against USD 14.64 at acquisition for a 24-sachet US generic carton.

Asia Pacific is worth USD 32.1 million, 26.2% of the total, and compounds at 2.79% to USD 42.3 million. Japan, where Mochida sells Beselna in 12-sachet packs, anchors the region; generic access elsewhere drives the growth.

North America is worth USD 24.9 million, 20.3% of global value, and grows only 0.92% a year to USD 27.3 million. US claims are rising but prices are falling faster, so revenue barely moves.

Latin America contributes USD 6.7 million and grows 2.18% a year to USD 8.3 million. The wildcard is the Middle East and Africa, at USD 4.4 million and 2.10% a year: tender wins for a single generic sachet supplier would move that line more than any other.

## Who supplies generic imiquimod cream, and who still sells Aldara and Zyclara?

Viatris, Sun Pharma and Mochida hold 32.1% of 2025 imiquimod cream value, by Douglas Insights estimate. Generic sachet makers and two legacy brand owners share the rest. In US Medicare, three generic suppliers wrote 99.8% of 2024 generic claims on the CMS count.

Viatris is the Aldara licence holder in the UK, per the [current SmPC](https://www.medicines.org.uk/emc/product/823/smpc), and Douglas Insights estimates it holds 15.8% of global imiquimod cream value on the strength of branded European sachet prices. Bausch Health holds the US new drug applications for both Aldara and Zyclara; Drugs@[FDA](https://www.fda.gov/) now lists [Aldara as discontinued](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020723), so its US position rests on Zyclara 3.75%, which held only 81 [Medicare claims](https://catalog.data.gov/dataset/medicare-part-d-spending-by-drug) in 2024. We estimate Bausch Health at 3.1%.

Sun Pharma owns Taro outright and sells imiquimod 5% under the Bascellex name in the UK; Taro wrote 20.8% of US Medicare generic claims in 2024 in the [CMS Part D data](https://catalog.data.gov/dataset/medicare-part-d-spending-by-drug), and Douglas Insights estimates Sun Pharma's combined share at 9.4%. Mochida sells Beselna 5% cream in Japan for genital warts and AK, an estimated 6.9% of global value.

Padagis, listed by CMS as Perrigo/Padagis, led [US Medicare generic imiquimod](https://catalog.data.gov/dataset/medicare-part-d-spending-by-drug) with 120,495 claims in 2024, or 56.5%, up from 40.8% in 2023. Glenmark wrote 22.6% of 2024 claims. Douglas Insights estimates Padagis at 5.7% and Glenmark at 4.2% of global value, with Oceanside, Sandoz and Teva as smaller US suppliers.

| Company | Main imiquimod cream position | Estimated global share 2025 |
| --- | --- | --- |
| Viatris | Aldara 5% sachets, UK and Europe | 15.8% |
| Sun Pharma (incl. Taro) | Bascellex 5%, US generic sachets via Taro | 9.4% |
| Mochida | Beselna 5%, Japan | 6.9% |
| Padagis | US generic 5% sachets | 5.7% |
| Glenmark | US generic 5% sachets | 4.2% |
| Bausch Health | Zyclara 3.75% and 2.5% | 3.1% |

## How much does a 24-sachet box of imiquimod cream cost a pharmacy?

A US pharmacy pays about USD 14.64 for a 24-sachet carton of generic imiquimod 5% cream. That is USD 0.61 per sachet on the latest National Average Drug Acquisition Cost (NADAC) file. A 7.5 g pump of generic 3.75% cream costs about USD 182.93 at acquisition.

Realised prices for imiquimod cream fall into three bands. Generic 5% sachets in the US sit at USD 0.61 per sachet at acquisition, and [Medicare Part D](https://catalog.data.gov/dataset/medicare-part-d-spending-by-drug) paid an average USD 2.00 per dosage unit in 2024, down from USD 2.69 in 2023, once pharmacy margins and dispensing fees are added.

The 3.75% band is far higher. Generic 3.75% pumps carry a NADAC of USD 24.39 per gram, or USD 182.93 per 7.5 g pump, and branded Zyclara drew USD 151.05 per [Medicare dosage unit](https://catalog.data.gov/dataset/medicare-part-d-spending-by-drug) in 2024.

The European branded band sits between them: GBP 48.60 for 12 sachets on the UK tariff, or GBP 4.05 per sachet. Douglas Insights blends all three bands, plus lower Asia Pacific prices near USD 16.60 a pack, into a global realised average of USD 28.40 per pack in 2025, falling to about USD 25.90 by 2035.

## Which regulators and label rules govern imiquimod 5% and 3.75% cream?

Imiquimod cream is prescription-only in every market we model, under labels first granted in 1997 in the US and 1998 in Europe. Those rules fix three indications and the sachet count per course. Payer policies then steer most scripts to the 5% generic.

The US Food and Drug Administration (FDA) approved Aldara under NDA 020723 on 27 February 1997, added actinic keratosis on 2 March 2004 and superficial basal cell carcinoma on 14 July 2004, per [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020723). Generics reach the market through abbreviated new drug applications (ANDAs) referencing that label.

Zyclara 3.75% was approved under NDA 022483 on 25 March 2010, with a new indication added on 24 March 2011, according to its [Drugs@FDA record](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022483).

In Europe, the [Aldara SmPC](https://www.medicines.org.uk/emc/product/823/smpc) records first authorisation on 18 September 1998 and was last revised in October 2025. It restricts AK use to the face and scalp of immunocompetent adults.

Japan's label for Beselna Cream 5%, sold by Mochida in 12-sachet packs, limits use to external genital and perianal warts and to AK on the face or scalp. Local formulary bodies add their own rules: Lancashire and South Cumbria lists imiquimod 3.75% as not recommended for NHS prescribing.

## How many sachets does one imiquimod treatment course use?

One imiquimod cream course uses between 12 and 48 sachets. An AK course takes 12, a 6-week sBCC course 30 and 16 weeks of wart treatment up to 48. That spread explains why US Medicare averages 18.3 sachets per claim across all three indications.

Those counts come straight from the [label schedules](https://www.medicines.org.uk/emc/product/823/smpc). AK on the 5% cream is three applications a week for 4 weeks, repeatable after a 4-week break, so 12 or 24 sachets. The 3.75% AK regimen is daily for 2 weeks, 2 weeks off, then 2 more weeks. Superficial BCC is five applications a week for 6 weeks.

[Medicare data](https://catalog.data.gov/dataset/medicare-part-d-spending-by-drug) confirm the mix. Generic imiquimod claims carried 3.91 million dosage units across 213,392 claims in 2024, an average of 18.34 per claim, up slightly from 18.13 in 2023. That figure sits between a 12-sachet AK box and a 24-sachet box, consistent with AK as the leading imiquimod cream indication.

## Did the Zyclara shortage in Canada expose a single-source risk for imiquimod 3.75% cream?

Yes: Zyclara 3.75% was short in Canada for 273 days, from 5 November 2024 to 5 August 2025, per the [Canadian shortage report](https://healthproductshortages.ca/shortage/237210). Bausch Health cited a production delay. The episode shows how thin brand-side imiquimod supply is outside the US generic sachet market.

The shortage report gave an estimated end date of 8 August 2025, and supply returned three days early. Douglas Insights assumes that over those nine months prescribers moved some AK patients to 5% sachets or other field creams, and treats that switching as permanent for a share of patients, one reason the 3.75% line grows more slowly than the 5% sachet in our model.

The US picture is the reverse of Canada. [Medicare data](https://catalog.data.gov/dataset/medicare-part-d-spending-by-drug) show only 81 Zyclara claims in 2024 against 213,392 generic claims, so a US brand outage would barely move volume. A generic sachet outage at Padagis, with 56.5% of Medicare generic claims, would be the larger risk.

## If generic sachet erosion deepens, what is imiquimod cream worth in 2035?

Under deeper erosion, imiquimod cream is worth USD 120.0 million in 2035 in our slower case. The base case gives USD 144.9 million and the faster case USD 171.2 million. A 1-point swing in pack growth shifts the 2035 value by USD 14.8 million.

The base case keeps volume at 2.6% and price at minus 0.9% a year, for 1.68% revenue growth and USD 144.9 million in 2035. Packs reach 5.58 million.

The slower case cuts volume to 1.4% and price to minus 1.6%, as tirbanibulin and fluorouracil take more AK courses and US sachet prices keep sliding at the recent Medicare pace. Our model then has revenue shrinking 0.22% a year to USD 120.0 million.

The faster case lifts volume to 3.7% and holds price near flat at minus 0.3%, on stronger sBCC uptake and another brand shortage like the [2024-2025 Zyclara gap](https://healthproductshortages.ca/shortage/237210) pushing patients to generics. That gives 3.39% growth and USD 171.2 million.

Published forecasts run from about 6.4% to 7.0% a year, well above our 1.68%. The gap comes from price: we use observed sachet acquisition costs and Medicare spend per claim, both falling, rather than list prices.

## Douglas Exclusive: the Imiquimod Sachet-to-Claim Ledger

The Imiquimod Sachet-to-Claim Ledger is a Douglas Insights model built from 19 inputs, all sourced price and volume figures. They are 12 Medicare Part D generic and manufacturer figures, 4 Zyclara brand figures, 2 NADAC acquisition prices and 1 UK tariff price. It reconciles what a pharmacy pays for an imiquimod sachet with what a payer reimburses per claim.

| Ledger line | 2023 | 2024 | Change |
| --- | --- | --- | --- |
| Medicare generic imiquimod claims | 186,313 | 213,392 | +14.5% |
| Medicare generic spend | USD 8.60 million | USD 7.30 million | -15.2% |
| Spend per generic claim | USD 46.18 | USD 34.20 | -25.9% |
| Sachets per claim | 18.13 | 18.34 | +1.2% |
| Padagis share of generic claims | 40.8% | 56.5% | +15.7 points |
| Zyclara brand claims | 90 | 81 | -10.0% |

The ledger's finding is blunt. By our count from the [CMS file](https://catalog.data.gov/dataset/medicare-part-d-spending-by-drug), Medicare paid 25.9% less per imiquimod claim in 2024 while dispensing 14.5% more claims, and one supplier, Padagis, took 56.5% of generic claims. Acquisition cost tells the same story: USD 0.61 per sachet at NADAC against USD 2.00 reimbursed per unit.

Douglas Insights reads the ledger as evidence that imiquimod cream volume is healthy and price is the weak leg. That is the basis for the minus 0.9% price assumption and for placing our revenue CAGR below published ranges.

## Methodology: how were imiquimod packs and sachet prices counted?

The imiquimod cream model multiplies 4.32 million packs by USD 28.40 per pack to reach USD 122.7 million in 2025. Five regional models feed it. Hard price or volume data anchor four countries, the US, UK, Canada and Japan, with 19 ledger inputs underneath.

US packs start from 213,392 Medicare generic claims plus 81 Zyclara claims, divided by an assumed 46% Medicare share of US imiquimod scripts, for about 0.46 million packs. Canada adds an assumed 0.06 million, so North America totals 0.52 million packs at USD 47.90 each, or USD 24.9 million.

Europe is 1.33 million packs at USD 41.05, Asia Pacific 1.93 million at USD 16.63, Latin America 0.33 million at USD 20.30 and the Middle East and Africa 0.21 million at USD 20.95. The five regions sum to 4.32 million packs and USD 122.7 million.

Cross-checks: segment 2035 values sum to USD 145.7 million, within 0.6% of the USD 144.9 million total, and regional 2035 values sum to USD 144.9 million. Medicare sachets per claim, 18.34, sit inside the 12 to 30 sachet range of the label courses. Related dermatology work includes our [Botulinum Toxin Market](https://www.douglasinsights.com/botulinum-toxin-market/) and [Mineral Sunscreen Market](https://www.douglasinsights.com/mineral-sunscreen-market/) reports, and the [Small Molecule Injectable Market](https://www.douglasinsights.com/small-molecule-injectable-market/) study covers adjacent generic pricing.

## Market by segment

| Segment | Share | Value |
| --- | --- | --- |
| Actinic keratosis | 51.8% | $63.6 Mn |
| External genital and perianal warts | 31.7% | $38.9 Mn |
| Superficial basal cell carcinoma | 16.5% | $20.2 Mn |

## Market by region (USD million)

| Region | 2025 | 2026 | 2035 | CAGR 2026-2035 |
| --- | --- | --- | --- | --- |
| Global | 122.7 | 124.8 | 144.9 | 1.68% |
| North America | 24.9 | 25.1 | 27.3 | 0.92% |
| Europe | 54.6 | 55.3 | 61.6 | 1.21% |
| Asia Pacific | 32.1 | 33 | 42.3 | 2.79% |
| Latin America | 6.7 | 6.8 | 8.3 | 2.18% |
| Middle East and Africa | 4.4 | 4.5 | 5.4 | 2.1% |

## Dataset

| Series | Value | Unit |
| --- | --- | --- |
| Market size 2025 | 122.7 | USD million |
| Market size 2035 | 144.9 | USD million |
| Revenue CAGR 2026-2035 | 1.68 | percent |
| Volume CAGR 2026-2035 | 2.6 | percent |
| Price per pack CAGR 2026-2035 | -0.9 | percent |

## Frequently asked questions

### What is imiquimod cream worth today, and what will it be worth in a decade?

USD 122.7 million in 2025, rising to USD 144.9 million in 2035 at a 1.68% revenue CAGR, built from 4.32 million packs at USD 28.40 each.

### Why do published imiquimod forecasts look so much higher than this one?

6.4% to 7.0% a year is the published range, against our 1.68%, because we price from observed sachet acquisition costs and Medicare spend per claim, both falling, rather than list prices.

### How many sachets does a typical imiquimod prescription contain?

18.34 dosage units per Medicare generic claim in 2024, between a 12-sachet AK box and a 24-sachet box; an sBCC course needs 30 sachets.

### What does a pharmacy pay for generic imiquimod 5% sachets?

USD 0.61 per sachet on the latest NADAC file, or USD 14.64 for a 24-sachet carton, while Medicare Part D paid an average USD 2.00 per dosage unit in 2024.

### Which supplier dominates US Medicare generic imiquimod claims?

56.5% for Padagis in 2024, with 120,495 claims, up from 40.8% in 2023; Glenmark wrote 22.6% and Taro 20.8%.

### How long did the Zyclara 3.75% shortage in Canada last?

273 days, from 5 November 2024 to 5 August 2025, after Bausch Health cited a production delay.

### Why is basal cell carcinoma the fastest-rising imiquimod indication?

2.96% a year, because a 6-week course of 30 sachets is an alternative to a surgical visit for suitable low-risk lesions, which Douglas Insights expects more older patients to take up.

### What happens to imiquimod revenue if sachet prices keep sliding?

USD 120.0 million in 2035 in the slower case, with volume at 1.4% and price at minus 1.6% a year, against USD 144.9 million in the base case.

## Sources

- [electronic medicines compendium (Viatris), Aldara 5% Cream summary of product characteristics](https://www.medicines.org.uk/emc/product/823/smpc)
- [Centers for Medicare and Medicaid Services, Medicare Part D Spending by Drug](https://catalog.data.gov/dataset/medicare-part-d-spending-by-drug)
- [US Food and Drug Administration, Drugs@FDA: Aldara NDA 020723](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020723)
- [US Food and Drug Administration, Drugs@FDA: Zyclara NDA 022483](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022483)
- [Drug Shortages Canada, Drug shortage report for Zyclara](https://healthproductshortages.ca/shortage/237210)
- [NHS Scotland Right Decisions, Actinic keratosis primary care pathway](https://www.rightdecisions.scot.nhs.uk/shared-content/cfsd/dermatology/actinic-keratosis/)
- [PMDA, Beselna Cream 5% package insert](https://www.pmda.go.jp/PmdaSearch/iyakuDetail/790005_6290701N1028_1_08)

## How to cite

Douglas Insights, "Imiquimod Cream Market", DI-HC-10465, updated 2026-10-04, https://www.douglasinsights.com/imiquimod-cream-market/